Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension

Core Viewpoint - Idorsia Ltd, in collaboration with Stanford Hypertension Center and Duke Heart Center, has launched the IMPACT-HTN program aimed at modernizing the management of difficult-to-control hypertension through a multi-phase initiative that incorporates AI technology and real-world evidence [2][3][4]. Group 1: Program Overview - The IMPACT-HTN program consists of three phases designed to standardize treatment protocols and improve patient outcomes for those with difficult-to-control hypertension [2]. - The initiative will generate real-world evidence and develop scalable AI-powered tools to assist in identifying patients who may benefit from innovative therapies, including Idorsia's TRYVIO™ [2][5]. Group 2: Collaboration and Goals - The program is led by Dr. Vivek Bhalla from Stanford and Dr. Sreekanth Vemulapalli from Duke, emphasizing a cross-institutional collaboration to enhance care coordination and access to new therapies [3][4]. - The goal is to standardize evaluation and management practices for hypertension, ultimately improving patient outcomes and addressing the global health issue of hypertension, which affects approximately 50% of adults in the U.S. [3][4]. Group 3: Tools and Innovations - The program will introduce a digital care algorithm to standardize assessment and management of difficult-to-control hypertension, utilizing interactive tools such as AI chatbots and patient-facing algorithms [6]. - A personalized hypertension risk score will be developed to better identify patients at risk for negative cardiovascular outcomes, allowing for timely intervention [6]. Group 4: TRYVIO™ Overview - TRYVIO, a dual endothelin receptor antagonist, is now available for prescription and is indicated for patients whose hypertension is not adequately controlled with other medications [7][18]. - It has been included in the new clinical practice guidelines from the American College of Cardiology and the American Heart Association, highlighting its significance in the treatment landscape [7].